The paper introduces CFKD-AFN, a cross‑fidelity knowledge distillation and adaptive fusion network that uses abundant low‑fidelity simulation data to improve personalized treatment outcome predictions from scarce high‑fidelity trial data. The dual‑channel distillation module extracts complementary knowledge from the low‑fidelity model, while an attention‑guided fusion module adaptively integrates multi‑source information. Experiments on chronic obstructive pulmonary disease data demonstrate significant reductions in mean squared error (6.67%–74.55%) and mean absolute percentage error (1.43%–51.54%) compared to competing methods, and the framework can be extended to an interpretable variant for feature‑attribution analysis.
arXiv:2608. 14657v1 Announce Type: new Abstract: Early identification of lung cancer risk is critical for timely intervention, yet existing prediction models are limited by their reliance on single data modalities and their inability to leverage structured clinical knowledge.
arXiv:2604. 16878v2 Announce Type: replace Abstract: Early prediction of severe clinical deterioration and remaining length of stay can enable timely intervention and better resource allocation in high-acuity settings such as the ICU.
arXiv:2606. 25762v1 Announce Type: new Abstract: In oncology, access to patient-level data is often restricted.
arXiv:2606. 31171v1 Announce Type: new Abstract: Acquiring comprehensive cross-domain biomedical profiles is often costly and time-consuming, resulting in severe data scarcity in medical research.
arXiv:2607. 04557v1 Announce Type: cross Abstract: Accurate prediction of patient-specific therapeutic response from pre-treatment transcriptomes is hindered by the scarcity of matched clinical response labels and post-treatment molecular profiles.
Accurate prediction of patient-specific therapeutic response from pre-treatment transcriptomes is hindered by the scarcity of matched clinical response labels and post-treatment molecular profiles. Preclinical transfer-learning models can simulate drug-induced expression changes but are often hard to interpret and unstable, whereas knowledge-graph methods provide mechanistic context yet remain static and fail to capture drug-induced transcriptomic perturbation dynamics.
arXiv:2607. 20453v1 Announce Type: cross Abstract: Large language models show promise for clinical prediction, but zero-shot performance on specialized tasks is limited by incomplete domain knowledge, especially for smaller locally deployable models.
arXiv:2608. 12805v1 Announce Type: new Abstract: Access to clinical data is essential for developing reliable healthcare machine learning systems, but direct use of electronic health records is constrained by privacy regulation, institutional review, data-use agreements, and the risk of re-identification.
arXiv:2607. 29462v1 Announce Type: cross Abstract: Adapting deep learning models to profound clinical heterogeneity typically relies on parameter-efficient fine-tuning (PEFT) to avoid the severe overfitting associated with full end-to-end network updates.
The paper presents a newly curated, multi-center, multi-modal, and longitudinal lung cancer dataset comprising 1,365 patients with whole-slide images, CT scans, PET scans, structured clinical data, transcriptomics, and follow-up information. The dataset features substantial, non-uniform missingness across modalities, making it ideal for evaluating robust multi-modal fusion strategies. Benchmarks on 12‑month overall survival, disease‑specific survival, and longitudinal hazard prediction demonstrate that integrating complementary modalities consistently outperforms uni-modal approaches, even under severe missing data.
A causal multi-modal AI model was developed to predict personalized chemosensitivity in breast cancer patients using routine pathology and clinical data. Trained on 9,141 patients from nine countries and validated on 1,994 patients from three countries, the model produced treatment-specific recurrence probabilities with near-perfect calibration and strong prognostic discrimination over 5- and 10-year horizons. It outperformed existing recurrence-score tests and could reduce chemotherapy prescriptions by 30% while maintaining recurrence-free rates, with predictive performance also transferring to non-breast cancers.
arXiv:2607. 20742v1 Announce Type: new Abstract: Multimodal learning is a robust approach to improve predictive performance in applications such as medical prognosis.